Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX – Get Free Report) shares fell 4.4% on Thursday . The stock traded as low as $17.38 and last traded at $17.50. 11,323 shares changed hands during trading, a decline of 64% from the average session volume of 31,666 shares. The stock had previously closed at $18.30.
Analysts Set New Price Targets
A number of brokerages recently issued reports on TLX. William Blair restated an “outperform” rating on shares of Telix Pharmaceuticals Limited American Depositary Shares in a report on Wednesday, March 12th. UBS Group lifted their price target on Telix Pharmaceuticals Limited American Depositary Shares from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Monday, January 27th.
Get Our Latest Stock Analysis on Telix Pharmaceuticals Limited American Depositary Shares
Telix Pharmaceuticals Limited American Depositary Shares Stock Down 1.5 %
About Telix Pharmaceuticals Limited American Depositary Shares
Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Recommended Stories
- Five stocks we like better than Telix Pharmaceuticals Limited American Depositary Shares
- 3 Best Fintech Stocks for a Portfolio Boost
- MarketBeat Week in Review – 03/24 – 03/28
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
- How to Buy Gold Stock and Invest in Gold
- 4 Healthcare Stocks With Massive Gains—and More to Come
Receive News & Ratings for Telix Pharmaceuticals Limited American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals Limited American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.